Connect with us


The ‘all hands on deck’ approach to medical device research at Cúram



Sam Cox shines a spotlight on Cúram, the Science Foundation Ireland research centre developing life-changing medical devices.

Across scientific research, ‘transdisciplinarity’ has become a buzzword. It is no longer enough to remain statically in a single academic area without linking in with your peers and seeing how other systems interact.

This is particularly prominent in medicine. The human body is an interlinked series of systems, organs and mechanisms. Some of these interplays are well-understood. Our interventions for when they go wrong are often straightforward and effective. Other interactions still elude us.

This is what Cúram, the Science Foundation Ireland research centre for medical devices, tries to remedy. Hosted by NUI Galway, their smart medical device technologies aim to find creative solutions to complicated problems.

Life-altering decisions

Take, for instance, diabetes. One of the key problems with type 2 diabetes is hesitancy to take insulin injections. Dislike of needles, stigma around medication for life and fear of the unknown often lead people to delay taking insulin injections, impacting the severity of ultimate health outcomes. It is problems like these that Cúram tackles.

By reimagining delivery systems, such as slow-release tablets for oral ingestion, there is a concentrated effort at making real differences through clever technology. To do this, disciplines as diverse as engineering, materials science, biochemistry, medicine, and social science converge with academics, industry and clinicians. Creating solutions means advancement not only within these sectors, but for medical innovation.

Choosing which solution to pursue is a magnified Sophie’s choice in medicine. Some work is short-term with little doubt of its requirement. During the early stages of the Covid-19 pandemic, researchers were involved in optimising ventilators to allow more patients to be treated with the same number of devices. Other projects are longer-term. In its previous research cycle, the Galway-based Cúram centre was a panoply of cutting-edge ideas and solutions, with 244 separate potentially breakthrough projects on the go. Of these, 16 have been carried forward – those with the most chance of realising life-altering technologies.

To carry these projects out, teams of engineers, clinicians, patients and researchers are assembled. Academics and industry come together. All of these assets are co-ordinated to address specific problems, all with the goal of melding outside systems into the factory of the human body.

Prof Abhay Pandit, director of Cúram, explains that careful criteria were developed, and an external world-renowned board of clinicians, academics and industry was set up to evaluate “How can we get concepts to the patient and what can we do to facilitate that?”

To get to the patient, Cúram needs support from industry, as its ultimate goal is to make technologies widely available. While Cúram deals with a variety of medical ailments, it has divided its next stage of research into three broad domains: soft tissue, musculoskeletal-neural, and renal-cardiovascular-metabolic. But when the crux of the objective is to improve quality of life, how can projects be compared?

What can be compared is what stage the research is at. Pandit describes one project centred around a gel to alleviate pathological symptoms after a heart attack. While this is a blue-sky project that is four to six years from fruition, the studies conducted are very advanced – a metric that puts them at the front for funding.

Moving from project to prototype is the aim of the centre in its next funding phase, and a central motivation for the increased transdisciplinarity. It’s an all hands on deck approach to get results in the immediate future.

The balancing act

In the left atrium of the heart there is a sac called the left atrial appendage. “It has no anatomical function – it’s just an evolutionary hangover,” said Dr Martin O’Halloran, whose research tackles atrial fibrillation.

For some patients, the heart pumps inefficiently and blood gets trapped in this sac. If blood sits, it clots, and can get back into the bloodstream. If it travels to the brain, it can cause a stroke. Currently, patients undergo two open-heart surgeries to fix the problem – three hours to fix the electrical issue and a second three hours to fix the mechanical problem by putting in a plug. O’Halloran and industry partners are working on developing a device that can be implanted alongside the electrical fix to achieve both surgeries in one go, effectively halving the time undergoing high-risk surgery.

Another Cúram project involves using thermal therapy to treat high blood pressure (hypertension). Affecting more than 1bn people worldwide, 12 to 18pc of cases are caused by abnormal hormone-secreting tumours on the adrenal glands. Currently, the most effective cure is to take the gland out with surgery – a solution that works when one gland is affected, but not when it’s both. These patients require a drug that often carries nasty side effects while lacking the same effectiveness. O’Halloran and his team want to burn these tumours off, saving the healthy tissue and solving the problem.

‘This is for societal good, even if the commercial case isn’t fully there yet’

After a few years working in academia as an engineer for medical devices, O’Halloran had become frustrated at the lack of research making its way to the clinic.

“I looked at groups nationally and internationally who were developing devices that made it to the clinic and the common denominator was in the groups where the project lead was a clinician, or groups that were physically located in a hospital,” he said.

This spurred the move of his engineering laboratory to the hospital, where the focus is always patient impact.

O’Halloran feels the strength of the Cúram is in allowing industry to come to the research centre with a problem, gaining access to a network of researchers that can tackle every aspect of that problem. Rather than trying to recruit a jack of all trades and master of none, Cúram has created a network where everyone knows the right person to go to. If industry can get access to universities, they get access to resources – and that’s when innovation becomes feasible.

According to O’Halloran, more than 90pc of the research is making incremental changes. It’s very hard to do disruptive research. “If you talk to medtech investors, you want a balanced portfolio. You want some incremental low-risk guaranteed to deliver, but you also want high-risk high-gain. In a way, I think the academic sector needs to do that. In my lab, if we went to a funder with a 10-year project, it’s a big ask to ask for funding. But if you prove yourself through smaller projects, you get a lot of credence and then they trust you on the more ambitious projects,” he said.

“We’re doing a project for blood pressure, and if you were to look at the commercial case, it’s not there yet. Loads of the pieces of the jigsaw are missing, because it is, at best, 10 years to fruition. But I love that, as an academic institution, we can look at that. This is for societal good, even if the commercial case isn’t fully there yet.”

This is where Cúram draws its strengths – not only from the interdisciplinarity of the fields within the centre, but its balance between industry and academia. Having worked in both, O’Halloran talks of the ‘rent-a-brain’ nature of consultancy work and being mined to solve a particular problem. Equally, academia often lacks the funding, or the practical applications needed to realise its conceptual ideas. He is clearly thriving in the balance.

Teaching new postdocs to navigate this borderline isn’t easy. “They’re used to answering questions thoroughly. You don’t give an answer until you know within a certain confidence interval that you’re correct,” said O’Halloran. Industry, on the other hand, wants the best guess at the present moment in time. It is about working on enough information to make the best next decision and having confidence that you will learn more and adjust accordingly as you go on. “Understanding that tension is really important,” added O’Halloran.

With more than 200 researchers trained within Cúram’s first research cycle, and 13 Innovative Training Networks specifically set up for its next phase, the centre is aiming to teach this interdisciplinarity as a language and navigate accordingly.

A blonde woman with wavy hair pictured against a dappled grey background.

Dr Karen Doyle. Image: Cúram/NUI Galway

Getting straight to the heart of the matter

In terms of a worldwide collaboration spanning countries and continents, we look to Dr Karen Doyle, who is at the epicentre of research into the cause of stroke.

Doyle is aiming to understand stroke at the level of composition. Blood clots can cause a blockage in the brain, leading to an ischemic stroke (versus a haemorrhagic stroke, which is caused by a rupture or tear in the blood vessel). Blockages can be caused by clots of all compositions. Yellow ones. Stringy ones. Ones filled with platelets or ones made of mainly red blood cells. Ones that can be removed in one go during a process called a thrombectomy, or ones that take repeated attempts. Some thrombectomies involve putting a stent retriever in and grabbing the clot, while others are sucked out through an aspiration device. There’s even recent evidence that some clots are caused specifically by Covid-19.

While strokes are distressingly common, affecting one in six men and one in five women globally, Doyle highlights how few forms of intervention have existed up until recently. Before the late 1990s, doctors were largely limited to providing care for the patient rather than any treatment. Then a drug called tissue plasminogen activator (tPA) was approved and some clots could be broken down, but only when they are fibrin-based (a tough, non-globular protein found in the blood).

With the advent of better imaging technology, it became increasingly possible to look into the brain and see what was going on in those suffering from strokes. In the mid-2000s, radiologists were able to see the vasculature of the brain and developed stent technology to reach clots. In fact, in 2015, Doyle explained, five seminal studies showed “without a shadow of a doubt” that feeding a medical device through the heart to reach the site of the clot and physically remove it is “hugely beneficial”.

These removed clots are now the samples that Doyle is collecting to build databases of clots in all their shapes and sizes from around the world. “When the clot is removed, we provide formalin pots to the hospital to collect the clot. We then courier the clots to our lab,” said Doyle. “The first thing we do is take a photograph. It’s amazing – even just studying the clots at that level, they look so different.”

After that, the clots are embedded into wax which gives them a stability to cut into thin slices of three micrometres, and tests are performed. Histology is first, where a stain called Martius Scarlet Blue is applied to reveal the microsocopic anatomy of the clot. Next is immunohistochemistry where an antibody is applied to selectively identify antigens in the cells, and in particular to look for the components that are related to aetiology. Finally, they use mass spectrometry to glean whatever further information is possible.

“For the Restore registry, we have Beaumont [Hospital in Dublin], but we also get clots sent to us from Gothenburg in Sweden, Budapest in Hungary and Athens in Greece,” she said. “We’re seeing similar findings to North American clots. However, Japan is an interesting new development. There is evidence that there is difference in an Asian population. Their diet is considerably different.”

Where O’Halloran focused on what Cúram could provide industry partners, Doyle highlights the close relationship with clinicians. In her case, the surgeons and doctors who are removing the clots and sending them samples. With more than 1,000 patients sampled, her team hopes to provide the groundwork that will eventually lead to industry design and, more immediately, a clinical understanding for their procedural approach. While they have industry partners, their publications and conference speakers make their discoveries known to all in the scientific community.

Doyle hammers home what Pandit had also made clear: that for all of Cúram’s projects, the central message is ‘we are ready to work with you on this’ and to tie all of the strands together for the sake of the patient.

This is what transdisciplinarity means for Cúram. Realising change for those affected when the interplay of bodily systems goes awry.

By Sam Cox

Sam Cox was named the science and technology winner in the 2020 National Student Media Awards (Smedias). This award category is sponsored by Science Foundation Ireland and includes a €1,000 bursary to support and encourage up-and-coming science and technology journalism.

The 2021 Smedias are now open for entries. The deadline for applications is 15 April 2021.

Source link


2021 iPhone photography awards – in pictures | Technology



The 14th annual iPhone photography awards offer glimpses of beauty, hope and the endurance of the human spirit. Out of thousands of submissions, photojournalist Istvan Kerekes of Hungary was named the grand prize winner for his image Transylvanian Shepherds. In it, two rugged shepherds traverse an equally rugged industrial landscape, bearing a pair of lambs in their arms.

Source link

Continue Reading


With Alphabet’s legendary commitment to products, we can’t wait to see what its robotics biz Intrinsic achieves • The Register



Alphabet today launched its latest tech startup, Intrinsic, which aims to build commercial software that will power industrial robots.

Intrinsic will focus on developing software control tools for industrial robots used in manufacturing, we’re told. Its pitch is that the days of humans having to manually program and adjust a robot’s every move are over, and that mechanical bots should be more autonomous and smart, thanks to advances in artificial intelligence and leaps in training techniques.

This could make robots easier to direct – give them a task, and they’ll figure out the specifics – and more efficient – the AI can work out the best way to achieve its goal.

“Over the last few years, our team has been exploring how to give industrial robots the ability to sense, learn, and automatically make adjustments as they’re completing tasks, so they work in a wider range of settings and applications,” said CEO Wendy Tan White.

“Working in collaboration with teams across Alphabet, and with our partners in real-world manufacturing settings, we’ve been testing software that uses techniques like automated perception, deep learning, reinforcement learning, motion planning, simulation, and force control.”

Tan White – a British entrepreneur and investor who was made an MBE by the Queen in 2016 for her services to the tech industry – will leave her role as vice president of X, Alphabet’s moonshot R&D lab, to concentrate on Intrinsic.

She earlier co-founded and was CEO of website-building biz Moonfruit, and helped multiple early-stage companies get up and running as a general partner at Entrepreneur First, a tech accelerator. She is also a board trustee of the UK’s Alan Turing Institute, and member of Blighty’s Digital Economic Council.

“I loved the role I played in creating platforms that inspired the imagination and entrepreneurship of people all over the world, and I’ve recently stepped into a similar opportunity: I’m delighted to share that I’m now leading Intrinsic, a new Alphabet company,” she said.

The new outfit is another venture to emerge from Google-parent Alphabet’s X labs, along with Waymo, the self-driving car startup; and Verily, a biotech biz. ®

Source link

Continue Reading


Charles River to create 90 new jobs at Ballina biologics site



Charles River is expanding its testing capabilities in Ballina as part of its partnership with Covid-19 vaccine manufacturer AstraZeneca.

Contract research organisation Charles River Laboratories is planning an €8m site expansion in Ballina to facilitate batch release testing for Covid-19 vaccines from AstraZeneca.

The expansion at the Mayo site will create an additional 1,500 sq m of lab space and 90 highly skilled jobs in the area over the next three years.

Click here to check out the top sci-tech employers hiring right now.

The company provides longstanding partners AstraZeneca with outsourced regulated safety and development support on a range of treatments and vaccines, including testing and facilitating the deployment of Vaxzevria for Covid-19 and Fluenz for seasonal infleunza.

The latest investment follows earlier expansions at the Ballina site and Charles River recently announced plans to establish a dedicated laboratory space to handle testing of SARS-CoV-2 and other similar pathogens that cause human disease.

“We are incredibly proud of the transformational changes we have implemented on site and the role that Charles River has played in supporting the safe and timely roll-out of AstraZeneca’s Covid-19 vaccine,” said Liam McHale, site director for Charles River Ballina.

“Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients.”

Charles River acquired the Ballina facility, which focuses on biologics testing, in 2002. The company employs 230 people at its two facilities in Ireland, including the Mayo site and a site in Dublin, established in 2017, which serves as the EMEA and APAC headquarters for the company’s microbial solutions division.

IDA Ireland is supporting the expansion. Mary Buckley, executive director of the agency, said Charles River is an “employer of long standing” in Co Mayo.

“The enhancement of its product lines and the development of additional capability at the Ballina facility is most welcome,” she added. “Today’s announcement is strongly aligned to IDA Ireland’s regional pillar and its continued commitment to winning jobs and investment in regional locations.”

Dan Wygal, country president for AstraZeneca Ireland, added: “Our Covid-19 vaccine, Vaxzevria, undergoes extremely robust safety and quality testing prior to becoming available for patients. We are committed to bringing safe, effective vaccines to Ireland and other markets as quickly as possible, and Charles River will continue to be an important partner in this regard.”

Source link

Continue Reading


Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates 
directly on your inbox.

You have Successfully Subscribed!